Key facts
- This page summarizes Marlyn Teresa Mathew's Form 3 filing for Zura Bio Ltd (ZURA).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2026, 16:55.
Marlyn Teresa Mathew - 17 Apr 2026 Form 3 Insider Report for Zura Bio Ltd (ZURA)
- Reporting relationship
- VP, Principal Acctg. Officer
- Issuer ticker
- ZURA
- Reported as of
- 17 Apr 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Kim Davis, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Marlyn Teresa Mathew filed Form 3 for Zura Bio Ltd (ZURA) on 22 Jun 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002137663
Primary reporting owner
Mathew Marlyn Teresa
- Relationship
- VP, Principal Acctg. Officer
- Address
- C/O ZURA BIO LTD, 1489 W. WARM SPRINGS RD. #110, HENDERSON
- Signature
- /s/ Kim Davis, Attorney-in-Fact
- Signature date
- 22 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZURA
holding
Class A Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 129,182
- Date
- 17 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZURA
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Apr 2026
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 37,505
- Exercise price
- Footnotes
- F2, F3
ZURA
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Apr 2026
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 11,133
- Exercise price
- Footnotes
- F4, F5
ZURA
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Apr 2026
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 90,000
- Exercise price
- $3.38
- Footnotes
- F6
ZURA
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Apr 2026
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 81,150
- Exercise price
- $1.20
- Footnotes
- F7
ZURA
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Apr 2026
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 66,220
- Exercise price
- $6.03
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Includes 32,296 shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.
Footnote F2
Immediately exercisable.
Footnote F3
$0.83732
Footnote F4
One fourth (1/4) of the shares subject to the option award vested on March 15, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) monthly installments thereafter on the last day of the month, subject to the Reporting Person's continuous service through such vesting date.
Footnote F5
$1.19593
Footnote F6
One fourth (1/4) of the shares subject to the option award vested on June 18, 2025 and the remaining shares subject to the option vested or shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F7
One fourth (1/4) of the shares subject to the option award vested on February 27, 2026 and the remaining shares subject to the option vested or shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F8
One fourth (1/4) of the shares subject to the option award shall vest on April 1, 2027 and the remaining shares subject to the option shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.